Two picks: VPHM and JBX# Investment - 投资
j*d
1 楼
VPHM, it actually is not a biotech company. It does not do research and develop, but buy good drug candidates.
Its principal product includes Vancocin for treatment of antibiotic- associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. The company also develops Maribavir, which is in Phase III clinical development stage for the treatment of cytomegalovirus disease; HCV-796 that is in Phase II
Its principal product includes Vancocin for treatment of antibiotic- associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. The company also develops Maribavir, which is in Phase III clinical development stage for the treatment of cytomegalovirus disease; HCV-796 that is in Phase II